Taxus Cardium Pharmaceuticals Group, Inc. (OTCMKTS:CRXM) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Item 5.02.
|
Departure of Directors or Principal Officers; Election of |
On December 14, 2016, Lon Otremba and Tyler Dylan-Hyde resigned
from our Board of Directors.Each director resigned to pursue
other interests, and not as a result of any disagreement with the
Company.Tyler Dylan-Hyde is a co-founder of the Company and
served as our General Counsel and Chief Business Officer from
December 2003 until December 2014. Lon Otremba had served on our
Board of Directors, including our Nominating Committee, since
January 2006.
We do not intend to appoint replacement directors.Following the
resignations and in accordance with provisions of our Bylaws, our
Board of Directors adopted a resolution to reduce the size of the
board from ten directors to eight.We currently have eight
directors serving on our board, including seven directors that
meet the definition of an independent director under the Nasdaq
marketplace rules.
We issued a press release relating to the resignations with is
attached as Exhibit 99.1 to this report.
Item 9.01. Financial Statements and Exhibits.
|
Exhibit No. |
Description of Exhibit |
|
99.1 |
Press Release issued December 14, 2016. |
|
SMRH:479902608.1 |
-2- |
About Taxus Cardium Pharmaceuticals Group, Inc. (OTCMKTS:CRXM)
Taxus Cardium Pharmaceuticals Group, Inc. is a holding company. The Company operates a medical technologies portfolio of investments, which include Angionetics, Inc. (Angionetics), Activation Therapeutics, Inc., To Go Brands, Inc. and LifeAgain Insurance Solutions, Inc. (LifeAgain). Angionetics is focused on the late-stage clinical development and commercialization of Generx (Ad5FGF-4), an angiogenic gene therapy product candidate. Activation Therapeutics, Inc. is focused on the development and commercialization of the Excellagen technology platform, which is a flowable dermal matrix for advanced wound care that has various applications as a delivery platform for small molecule drugs, proteins and biologics. LifeAgain has developed an advanced medical data analytics (ADAPT) technology platform focused on developing various products for the life insurance and healthcare sectors. It has an investment in Healthy Brands Collective, a functional food and nutraceutical company. Taxus Cardium Pharmaceuticals Group, Inc. (OTCMKTS:CRXM) Recent Trading Information
Taxus Cardium Pharmaceuticals Group, Inc. (OTCMKTS:CRXM) closed its last trading session 00.000 at 0.169 with 3,225 shares trading hands.